Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab for Chronic Headache in Idiopathic Intracranial Hypertension
NCT07645833Phase 3Not yet recruiting
- Start
- Jun 2026
- Primary completion
- Jun 2028
01
Overview
Phase 3, randomised, double-blind trial in idiopathic intracranial hypertension (IIH) comparing Eptinezumab with Placebo (2 arms). Primary endpoint: Mean monthly moderate-to-severe headache days at 12 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
eptinezumab
03
Conditions
idiopathic intracranial hypertension (IIH)
Beyond the preview
Go deeper on NCT07645833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07645833.